Actively Recruiting
Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis
Led by Institut Pasteur · Updated on 2025-05-14
90
Participants Needed
1
Research Sites
341 weeks
Total Duration
On this page
Sponsors
I
Institut Pasteur
Lead Sponsor
J
Janssen Biotech, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).
CONDITIONS
Official Title
Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (over 18 years old)
- Diagnosed with cutaneous psoriasis
- Signed informed consent to participate
- Covered by health insurance (except for AME) for Group 1 patients
- Require systemic treatment for psoriasis
- Have not previously received biological therapies
- For Group 2: Require anti-IL-23 biologics (guselkumab, risankizumab, tildrakizumab) as decided by their physician
- For Group 2: Either biologic-naive or received only one biologic with at least 4 months wash-out period
You will not qualify if you...
- Under 18 years old
- Pregnant or breastfeeding
- Immunocompromised
- Under legal protection, curatorship, or guardianship
- Refuse consent
- Unable to comply with study requirements due to geographic, social, or psychiatric reasons
- Beneficiary of the AME (only for Group 1 patients)
- Have previously received biologics (only for Group 2 patients)
- Contraindication to chosen biotherapy
- Received biologics within the last 4 months
- Treated with two or more biologics
- Already received an anti-IL-23 biologic
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Lars ROGGE
Paris, Île-de-France Region, France, 75015
Actively Recruiting
Research Team
L
Lars Rogge
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here